article · Benha Medical Journal
Background: Muscle atrophy is a major clinical feature of chronic obstructive pulmonary disease (COPD), and it is considered a strong predictor of mortality in COPD patients. This study aimed to assess the use of serum creatinine/serum Cystatin C ratio in the assessment of muscle wasting and disease severity in stable COPD patients. Methods: This case-control study included 70 COPD patients and 20 age and gender-matched healthy controls. Pulmonary function tests, measurement of the serum creatinine (Cr) and cystatin C (Cys-C) levels, chest high-resolution CT images (HRCT) for the assessment of low attenuation area percentage (LAA%) and Erector Spinae muscle (ESM) thickness, routine laboratory investigations and arterial blood gases (ABG). Results: There was a significant positive correlation between serum cystatin c and severity of COPD and LAA% but there was a significant negative correlation between serum cystatin c and Erector Spinae muscle cross-sectional area (ESMCSA), forced vital capacity %predicted (FVC% predicted), forced expiratory volume in 1 second (FEV1%predicted) FEV1/FVC%, and body mass index (BMI). Moreover, there was a significant positive correlation between creatinine/ cysC ratio and BMI, ESMCSA, FVC% predicted, FEV1/ FVC % and FEV1% predicted. The cut-off points of ESMCSA and Cr/Cys C for severe COPD were 23.4 cm2 and 0.87 respectively. Conclusion: The present study indicated that the Cr/Cys C ratio is an easy, inexpensive, repeatable, and promising tool that allows us to evaluate muscle wasting in COPD patients using serum markers as there is a positive correlation between the degree of muscle wasting and the severity of COPD.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21608/bmfj.2024.284759.2065
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.